Low molecular weight peptidomimetic inhibitors with hydrophobic pocket binding properties and moderate fusion inhibitory activity against HIV-1 gp41-mediated cell fusion were elaborated by increasing the available surface area for interacting with the heptad repeat-1 (HR1) coiled coil on gp41. Two types of modifications were tested: 1) increasing the overall hydrophobicity of the molecules with an extension that could interact in the HR1 groove, and 2) forming symmetrical dimers with two peptidomimetic motifs that could potentially interact simultaneously in two hydrophobic pockets on the HR1 trimer. The latter approach was more successful, yielding 40 -60 times improved potency against HIV fusion over the monomers. Biophysical characterization, including equilibrium binding studies by fluorescence and kinetic analysis by Surface Plasmon Resonance, revealed that inhibitor potency was better correlated to off-rates than to binding affinity. Binding and kinetic data could be fit to a model of bidentate interaction of dimers with the HR1 trimer as an explanation for the slow off-rate, albeit with minimal cooperativity due to the highly flexible ligand structures. The strong cooperativity observed in fusion inhibitory activity of the dimers implied accentuated potency due to the transient nature of the targeted intermediate. Optimization of monomer, dimer or higher order structures has the potential to lead to highly potent non-peptide fusion inhibitors by targeting multiple hydrophobic pockets.
Introduction
The hydrophobic pocket (HP) on the surface of the gp41 trimeric HR1 coiled coil is an important target for antiretroviral drugs against HIV fusion. 1 The pocket sits at the interface between HR1 and helical HR2 segments which wrap down the sides of the coiled coil to form a six-helix bundle structure upon successful virus -host membrane fusion ( Figure 1A ). 2, 3 The pocket is exposed to inhibitors for 20 -30 minutes during a conformational change of gp41 prior to six-helix bundle formation. 4 Small molecules that bind in this pocket have been developed into low to sub-µM inhibitors of HIV entry, [5] [6] [7] [8] but so far efforts at small molecule discovery have failed to achieve the potency afforded by C-peptides derived from HR2. 9, 10 These are nM inhibitors, including T20 which is an FDA-approved fusion inhibitor. 11 Non-peptide inhibitors of HIV fusion could have advantageous properties as drugs, such as longer half-life and lower cost and the potential for oral bioavailability.
One approach to improving potency of small molecules is to extend them to form additional interactions with HR1 beyond the hydrophobic pocket. HR1 has multiple potential interactive sites both within a single groove and between adjacent grooves of the trimer.
Bidentate ligands are generally 1 -2 orders of magnitude more potent than their monomeric counterparts against targets with more than one binding site. 12, 13 To our knowledge, this concept has not been tested with small molecule inhibitors targeting gp41. For C-peptides, the effect of multivalent interactions is clear. 18 residue HP-binding C-peptides containing the motif WxxWDxxI are low µM binders 14, 15 and fusion inhibitors, 16 , while 34 residue C-peptides have low nM activity. 17 Dimerization of 22 residue helical C-peptides improved activity by a factor of 9. 18 Similarly, D-peptides designed to bind in the hydrophobic pocket 19 have activity improved by 10 -300 fold upon dimerization with a long polyethylene glycol (PEG) linker, presumably by simultaneous interactions in two HP's of the trimer. 20, 21 An important consideration in designing extension or dimerization of small molecule hydrophobic pocket binders is selection of a tether that will not disturb the binding mode. Helical peptidomimetics are suitable candidates for this approach because they are designed to emulate the amphipathic C-peptide helix, which has HP binding residues on one face of the helix ( Fig   1B) . Peptidomimetic inhibitors are expected to have side chains occupying the pocket while the nonpeptidic "backbone" is exposed above the pocket and available for tethering.
We previously examined a combinatorial library of three-subunit peptidomimetics ]-R 1 -OH , developed by the Boger group. 22 Screening with a binding assay for the gp41 hydrophobic pocket revealed a clear propensity for aromatic residues at R 1 and R 2 , especially for Trp, Nap and Phe4Cl. 23 Ile was also well-tolerated at R 1 in three subunit compounds with an aryl R 3 , consistent with the inhibitors emulating the Trp or Nap and R 1 = Trp, Nap or Phe4Cl were the optimal choices. Bioactivity was reduced by a factor of ~4 compared to the three subunit compounds listed. -Nap-OH confirmed this binding mode. 24 We selected two subunit compounds with R 1 = Trp or Phe4Cl and R 2 = Trp to explore attachment of a tether to the aryl alkoxy moiety, and to evaluate the effect of extension or dimerization on binding affinity and inhibition of virus -cell and cell -cell fusion.
Materials and Methods

Synthetic chemistry
2.1.1. Sources 3-fluoro-4-nitrobenzoic acid was purchased from Matrix Scientific (Fisher), 3-(2-hydroxyethyl)indole, Zn nanopowder, was purchased from Sigma-Aldrich. THF was purchased from EMD Millipore (VWR). 4-chlorobenzylalcohol was purchased from Alfa Aesar. Ltryptophan tert-butyl ester hydrochloride was purchased from Chem-Impex International.
Preparation of the aryl subunits
The aryl subunits were synthesized following the general procedure described previously. Hz), 2.14 (t, 2H, J = 7.6 Hz), 1.53 (t, 2H, J = 7.6 Hz), 1.43 (t, 2H, J = 7.6 Hz), 1.25 (m, 2H). 
11.
Assays
Fluorescence binding assay Inhibition constants K i for binding in the hydrophobic
pocket were determined using a fluorescence intensity assay as previously described. 
where L t , R t and I t are the concentrations of probe, HP binding sites in receptor Fe(env2.0) 3 , and inhibitor, respectively, K I1 and K I2 are the inhibition constants for the first and second binding interactions. The observed fractional fluorescence was calculated from equation (3).
The fit of calculated to observed data was determined from the sum of squares (equation (2)):
where F obs,i and F calc,i are the fractional fluorescence and s i is the standard deviation of each data point. µl/min, to ensure that any ferrous ion leached at low pH was restored. Any non-specifically bound material was removed with 50 µl of 500 mM NaCl at 50 µl/min. An equivalent reference surface was generated using the same procedure as above excluding the Fe II (envC) 3 coupling step. Analytes were detected at serially increasing concentrations from 0.098 to 50 µM in Hepes buffered saline (20 mM Hepes, 150 mM NaCl) at pH 7.0 containing 1% DMSO, using a 60 s association time and 300 s dissociation time. DMSO bracketing was used to correct the refractive index. Analysis of sensorgram data was carried out with Biacore Biaevaluation software. expressing CD4, CCR5 and CXCR4, 26 and containing an integrated reporter gene for firefly luciferase under control of HIV-1 LTR. 27 Effector cells were HL2/3 (#1294, contributed by B.K.
Surface Plasmon Resonance Experiments
Cell-cell Fusion Assay
Felber and G.N. Pavlakis) which produce HXB2 Env, Tat and Rev. 28 Serially diluted inhibitors were added to 96 well plates containing 25,000 TZM-bl cells per well cultured overnight.
50,000 HL2/3 cells were added per well, and fusion allowed to proceed for 6 hours in reduced serum medium (Gibco) with a final concentration of 1% DMSO. Luciferase expression was measured using Luciferase Assay Reagent (Promega) according to the manufacturer's instructions. Controls containing 1% DMSO with and without HL2/3 cells were measured for each compound, and experiments were performed in triplicate. MAGI-CCR5 cells from Dr. Julie Overbaugh. 33, 34 For MAGI antiviral assays, MAGI-CCR5 cells were grown overnight in 96 well plates in DMEM supplemented with 10% FBS, using 10,000 cells per well. The following day the medium was removed and compounds diluted in medium were added (6 dilutions in triplicate at each dilution), followed by the addition of either HIV-1 Ba-L (CCR5-tropic assay) or HIV-1 IIIB (CXCR4-tropic assay) at approximately ten 50% tissue culture infective doses per well (~10 TCID 50 /well). Assay plates were incubated for 48 hours, after which medium was removed and HIV-1 Tat-induced β-Gal enzyme expression was determined by chemiluminescence using Tropix Gal-Screen (Applied Biosystems) according to the manufacturer's instructions. MAGI attachment assays were performed similarly, but with a washout of unbound virus and compounds three (3) hours post-infection.
4 Viral Replication and Attachment Assays
Assays were conducted at a serum concentration of 2%.
Cytotoxicity Assay
The cytotoxic effect of the compounds was determined using the identical cell culture procedure to that described above for viral replication or cell-cell fusion, but measuring cell viability, using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS, CellTiter 96 reagent; Promega; used for MAGI assays) or using a resazurin cell viability reagent (Alamar Blue or Presto Blue, Life Technologies; used for cell-cell fusion assays) following the manufacturers' protocols.
Computational docking
Ligand charges and low energy conformations were obtained using OpenEye software 35, 36 (fixpka, molcharge, omega2-2.5.1.4 and szybki, OpenEye Scientific Software, Santa Fe, NM.
http://www.eyesopen.com). Compounds were docked into pdb structure 3P7K using Autodock Vina. A model of bivalent binding of the dimer 7 ( Figure 3 ) was obtained using low energy conformers of two partial structures, split at the edge of the PEG 3 linker. Structures were docked and linker dihedrals were manually adjusted to reconnect the two parts. The local geometry was then optimized and clashes removed using the default minimization protocol in Chimera (UCSF) (Potential energy of complex -12.4 x 10 3 , RMSD 0.0244 Å over 2460 atoms).
Results
Synthesis and Description of Compounds
Six compounds were prepared as shown in Figure   2 and Schemes 1 -3. There were two series, based on the two-subunit peptidomimetic tropic). The results are shown in Figure 4 and Table 1 . CCF was inhibited more readily than VCF, and augmenting the basic monomer significantly improved anti-fusion activity. None of the compounds exhibited any toxicity at the concentrations tested.
Scheme 3. Addition of a hydrophobic tail to monomers 3 and 4, forming 10 and 11 Dimerization of the inhibitors with a 22Å PEG linker connecting two monomers resulted in the best performing member of each series, with compounds 7 and 8 having IC 50 's < 1 µM against CCF and 3-5 µM against VCF. In this case, it is not expected that the PEG linker would interact extensively with the membrane, 20 suggesting that additional HR1 interactions could form the basis of the improved activity. We noted that the antiviral activity of 7 reached a plateau at ~20% residual fusion activity of Ba-L virus and ~6% residual fusion activity of IIIB virus. The faster kinetics of Ba-L fusion may limit the potency of the largest molecular weight inhibitor 7.
Solution binding studies confirmed hydrophobic pocket binding
Next we wished to ascertain whether the 50-fold increase in potency was a cooperative effect of dimers binding into two HP's of one HR1 trimer, as designed. We therefore examined whether binding and kinetic data could discriminate between a monovalent and bivalent binding mechanism. Affinity of the compounds for the gp41 HP was determined by fluorescence using a competitive inhibition assay that has been previously described. 14, 25 Briefly, the hydrophobic pocket (receptor R) is formed by metal ion assisted association between three HR1 peptides env2.0 spanning the pocket sequence (HXB2 residues 560 -584) that are covalently linked to N-terminal 2,2'-bipyridine was calculated analytically according to the equation
R t , I t and L t are the total concentrations of added receptor binding sites, inhibitor and probe peptide respectively, and K I is the inhibition constant. Equation (4) is an analytical approximation valid when R t >> L t which is fulfilled by the experimental conditions. Equation 11, conducted using 7.2 µM R t and 30 nM L t , are shown in Figure 5A and 5B. Here too, we observed that low µM inhibition in the binding assay was commensurate with activity against HIV-Env mediated fusion; however it was not completely correlated. A higher concentration was required for 50% activity of dimer compared to the corresponding extended monomer in the fluorescence assay, while dimers were clearly more potent in biological assays. Additionally, the slope of the binding curves was lower for the bivalent inhibitors. Parameters F L , R t and K I were determined from dose response curves by fitting to equations 1 and 2, and / or by numerical simulation. Results are given in Table 2 . (3) and (4) or (1), and the sum of squares SSQ was calculated using equation (2) A third option for data fitting involves monodentate binding for all of the dimers, with a significant degree of receptor aggregation occurring during the assay. We cannot formally rule out this possibility, given that the inhibitors are quite hydrophobic. We therefore turned to surface binding studies to evaluate inhibitor interactions. to verify our interpretation of the solution equilibrium binding studies. Furthermore, we were curious to know whether kinetics, especially off-rate could be correlated more effectively to observed biological potency than K I , given that the target is a transient intermediate structure.
Surface binding studies yielded kinetics of binding
Previous studies have shown that on-rate can limit the effectiveness of a large protein inhibitor, 38 and high potency is accompanied by a slow off-rate. 21, 39 SPR experiments were conducted on a Biacore CM5 chip using a modified version of the receptor peptide Fe(envC) 3 . The peptide envC is terminated by a D-cysteine residue, which orients the thiol group along the axis of the peptide and permits vertical anchoring of the receptor to the surface groups. We have previously used this receptor in electrochemical and SPR binding studies of peptide and small molecule -gp41 HP interactions. 40 The design creates a homogeneous ligand surface with open binding sites on the three faces of the three-fold symmetrical receptor, such that dimers could simultaneously bind into two pockets, if that is indeed their mechanism.
We achieved immobilization responses in the range 2460 -5670 units, corresponding to approximately one Fe(envC) 3 molecule per 32.6 -8.3 nm 2 , respectively, or effective concentrations between 2.6 -6 mM. 41, 42 A reference channel was prepared without receptor, and signals from this channel were subtracted out to yield SPR sensorgrams that reflected interactions with Fe(envC) 3 . Specificity of analyte binding was confirmed by observing both analyte and Fe(envC) 3 concentration dependent responses (Supplementary Data, Figure S3 ).
Typically, below ~10 µM, analyte responses were well below 100 RU, suitable for kinetic analysis. At higher concentrations, most compounds gave disproportionately high analyte responses, likely due to non-specific binding or aggregation. These sensorgrams were not included in the analysis.
We measured the association rate (k a ), dissociation rate (k d ) and rate constant (
for each compound at various concentrations, by analyzing sensorgrams using Langmuir 1:1 binding and 1:2 binding kinetic analysis. The maximum analyte response, RU max , occurring at saturating concentrations of analyte, was not obtained experimentally due to non-specific aggregation, and was determined from a good fit to SPR data for compound 7. Remaining sensorgrams were fit by fixing RU max proportionately according to the molecular weight of the analyte. Uncertainty in RU max led to ~30% uncertainty in k a , but still allowed us to compare kinetics within the compound set. Off-rate k d was less dependent on RU max . The results are reported in Table 3 
A bivalent model gave an improved fit to the SPR data for the dimers We observed
improved fits to the data for the dimers using a bivalent analyte binding model provided by the Biacore software, (Figure 7D and S4D) . The results of the data fitting are shown in Table 4 . The observation that k d1 > k d2 suggested that bivalent interactions make an important contribution to slowing the off-rate, and therefore to potency against fusion.
Kinetic rates correlated with inhibitor potency
The relatively small change in K I between monomers and dimers can be explained by the high entropic penalty due to constraining the flexible structures. 7 and 8 have 35 and 33 rotatable bonds, respectively, 19 of which involve the flexible succinimidyl-PEG 3 linker. 43 For the extended monomers, observed K I were lower and k a 's higher than for the dimers, confirming that the additional hydrophobic contribution to enthalpy more than offset the entropic penalty due the 18 -19 added rotatable bonds. The biophysical properties of the dimers provided evidence that slow kinetics was a more important quality for inhibiting fusion than the K I , since 7 and 8 were more than an order of magnitude more potent as fusion inhibitors than 3 and 4, and several times more potent than 10 and 11. They also explain the lower correlation observed between fusion inhibition and K I compared to k d , as shown in Figure 8 . We note that k a also correlated with inhibitor potency (not shown).
Discussion
In this study, we evaluated the binding affinity, kinetics and biological activity of peptidomimetic inhibitors that were modified to extend interactions with gp41 beyond the HP. consequence of the large number of degrees of freedom in the dimers. 44 The variation of K I 's across the data set was lower than the differences in their biological activity. The 6-fold reduction in K I caused by adding a flexible hydrophobic tail in 10 and 11
improved biological activity by a factor of 10 -15, while dimers 7 and 8 were 40 -60 fold more active than the monomers against fusion, despite only 2 -3 fold changes to <K I >. Examination of the kinetic data revealed that dissociation rate k d was better correlated to biological activity than K I . Dimers dissociated ~ 20 times more slowly than monomers.
k a also decreased with increasing size of the inhibitors, a consequence of both size and the loss of conformational entropy upon binding. 44 Consequently, the range of K I = k d /k a remained small. This is the enthalpy -entropy compensation effect, whereby structural mobility provided for enthalpic contributions through enhanced conformational search space and number of interactions, but simultaneously resulted in a large entropic penalty from inhibitor rigidification upon binding. 43 In this context, even the monomeric units with 8 -9 rotatable bonds have poor avidity. The number of rotatable bonds increased to 18-19 for 11 and 10, and 33 -35 for 8 and 7, clearly a limiting factor in the potency of the resulting molecules. It also affected the degree of cooperativity of bidentate binding in the dimers. Slight cooperativity was apparent from the lower average inhibition constant of dimers compared to monomers and the observation of K I2 << K I1 , and k d2 < k d1 in bivalent model fitting, but it was significantly dampened by the length and flexibility of the spacer between the two monomers, resulting in a large K I1 and low k a1 .
By contrast, there was significant cooperativity observed in fusion inhibitory activity of the dimers, suggesting that the biological milieu is not emulated by the biophysical setup. A factor of 2 -3 in <K I > became a factor of 40 -60 in IC 50 . One possible explanation is that the transient nature of the biological target accentuates the role of inhibitor kinetics in potency.
Previous studies have shown that potency of HP binding inhibitors is highly dependent on the rate of the fusion reaction. 21 The low off-rate for the dimers could result in gp41 molecules trapped in the inhibitor-bound state or cause an off-pathway effect. 39 Another possibility is that the local environment of gp41 near the membrane alters the behavior of the inhibitors due to association of hydrophobic moieties with lipids. Addition of a lipid-binding moiety to a peptide is known to enhance peptide potency by orienting and concentrating the peptide at the site of action. [45] [46] [47] Yet a third possible explanation is that the cooperativity does not arise from bidentate interactions with one HR1 trimer, but rather by the bridging of two trimers on the cell or virion surface. This was suggested to be the mechanism of 20 -100 fold increased potency of bivalent sialosides against Influenza Virus mediated hemagglutination, where, similar to our observations, a minimal increase in binding affinity to an isolated trimer occurred for the dimers. 48 This mechanism appears somewhat less likely due to the low receptor density on the surface of HIV, where there are estimated to be ~ 14 Env trimers per virion, compared to ordered arrays of 500 -1000 HA trimers per Influenza virion. 48, 49 However, if more than one HIV Env trimer congregates to form the fusion pore, it could provide a window of susceptibility for a dimer bridge. The number is not known and has been variously thought to be one or a few. 
Conclusion
In conclusion, we have observed ~ 50 fold improvement in fusion inhibitory activity upon dimerization of small peptidomimetic two-subunit compounds containing Trp and Phe4Cl residues. Off-rate was found to be a more sensitive predictor of fusion inhibitory activity than K I . Our data are consistent with bidentate binding of the dimer molecules to the gp41 trimer, with slow dissociation rates due to rebinding events, notwithstanding the low cooperativity of dimer binding. The failure of solution binding to recapitulate the cooperative effect observed in fusion inhibition is likely due to linker flexibility and to the effect of kinetics on the inhibitory potency of the dimers. By way of comparison, a range of 10 -300 fold improvement in fusion inhibitory activity was found by dimerizing D-peptide inhibitors, a variation that was related to the viral strain-dependent rate of fusion. 20, 21 Trimerization of D-peptides improved activity by a factor of 1000 or more. 20, 21 The mechanism was assumed to be due to tridentate binding to one HR1 trimer, but no specific experiments confirmed this binding mechanism. We have shown that multimerization is an applicable strategy for improving non-peptide fusion inhibitors. Local modifications to the structures to improve their thermodynamic parameters, as well as globally increasing multivalency, could yield orders of magnitude increase in potency. Importantly, these inhibitors utilize specific HP interactions rather than non-specific hydrophobic or electrostatic interactions 51 which can yield low µM binding to gp41 HR1 but are difficult to optimize. In this regard, it is likely that non-specific hydrophobic interactions will limit our ability to optimize inhibitors such as 10 and 11. Our results demonstrate proof of principle of a method to enhance avidity of non-peptide fusion inhibitors by focusing on multiple HP interactions.
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Figure Captions Inhibition constant K I plotted against cell-cell fusion IC 50 . Data were obtained from Tables 1 -3 .
